The role and function of CD4+ T cells in hepatic ischemia-reperfusion injury. (2nd January 2022)

• Record Type: Journal Article
• Authors: Wang, Jinglin; Xia, Senzhe; Ren, Haozhen; Shi, Xiaolei
• Is Part Of: Expert review of gastroenterology & hepatology. Volume 16:Number 1(2022)
• Page Start: 5
• Page End: 11
• Publication Date: 2022-01-02
• Subjects: Liver ischemia-reperfusion injury -- cd4+ t cell -- th1 -- treg -- th17 -- cytokine; Gastroenterology -- Periodicals; Liver -- Diseases -- Periodicals; 616.3
• DOI: 10.1080/17474124.2022.2020642
• Languages: English
• ISSNs: 1747-4124

Abstract

ABSTRACT: Introduction: Hepatic ischemia-reperfusion injury (IRI) is a severe complication frequently encountered in liver surgery, seriously affecting the therapeutic effects, tissue function. Various immune cells are involved in hepatic IRI, including macrophages, NKT cells, DCs, CD4 + T cells, and CD8 + T cells, among which CD4 + T cells play a critical role in this process. This article aims to summarize the functions and changes in various CD4 + T cell type counts and related cytokine levels in hepatic IRI and to review the possible mechanisms of mutual conversion between T cell types. Areas covered: We have covered the functions and changes that occur in Th1, Th17, and Treg cells in liver IRI, as well as the pathways and factors associated with them. We also discuss the prospects of clinical application and future directions for therapeutic advances. Expert opinion: This section explores the current clinical trials involving CD4 + T cells, especially Tregs, explains the limitations of their application, and summarizes the future development trends of cell engineering and their combination with the CAT technology. We also provide new ideas and therapeutic targets for alleviating liver IRI or other liver inflammatory diseases.